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War wound infection and osteomyelitis caused by
multidrug-resistant (MDR) Acinetobacter species have
been prevalent during the 2003–2005 military operations in
Iraq. Twenty-three soldiers wounded in Iraq and subse-
quently admitted to our facility from March 2003 to May
2004 had wound cultures positive for Acinetobacter cal-
coaceticus-baumannii complex. Eighteen had osteo-
myelitis, 2 burn infection, and 3 deep wound infection.
Primary therapy for these infections was directed antimicro-
bial agents for an average of 6 weeks. All soldiers initially
improved, regardless of the specific type of therapy.
Patients were followed up to 23 months after completing
therapy, and none had recurrent infection with
Acinetobacter species. Despite the drug resistance that
infecting organisms demonstrated in this series, a regimen
of carefully selected extended antimicrobial-drug therapy
appears effective for osteomyelitis caused by MDR
Acinetobacter spp.
C
asualty statistics from the 2003–2005 military opera-
tions in Iraq show an increase in the ratio of wound-
ed to fatal casualties compared to previous operations in
the Persian Gulf, Vietnam, and Korea (1). This relative
increase of wounded casualties has led to an increased
incidence of war wound infection and osteomyelitis, espe-
cially caused by multidrug-resistant (MDR)
Acinetobacter species. The incidence of bacteremia at
military medical facilities caused by Acinetobacter bau-
mannii has also increased (2). The current incidence of
infection with Acinetobacter  should not be surprising.
These organisms were the most frequently recovered
gram-negative isolate from war wounds and the second
most frequent bacterium causing bloodstream infection in
US Marines with extremity wounds during the Vietnam
War (3). In nonconflict environments, Acinetobacter
species are rarely responsible for community-acquired
infections. In the hospital setting, Acinetobacter species
are an important cause of nosocomial infection, yet these
infections were rarely encountered in our facility until we
began observing them in soldiers with infected wounds.
Nosocomial infections caused by Acinetobacter  species
include pneumonia, meningitis, bloodstream, urinary tract,
surgical wound, and soft tissue infections (4). Such infec-
tions are challenging to treat because of extensive antimi-
crobial drug resistance. Osteomyelitis caused by
Acinetobacter occurs, but it is less frequently reported and
had not been identified in our facility during the 14 months
before March 2003. Optimal therapy for osteomyelitis
caused by these organisms is not well defined because of
limited available data. This case series reviews 1 military
medical center’s experience with these infections, includ-
ing species identified, antimicrobial drug–susceptibility
patterns, antimicrobial drug therapy, and clinical outcomes. 
Methods
Case reports were compiled from active-duty soldiers
admitted to Brooke Army Medical Center (BAMC) in San
Antonio, Texas. This tertiary military medical center
serves a population of active-duty and retired soldiers and
their dependents along with a limited number of civilian
trauma patients admitted from the local area. The hospital
was operating at an average capacity of 175 beds during
the study period. This facility also houses the US Army’s
Institute of Surgical Research, which treats both active-
duty and civilian trauma patients with burn injuries. Data
collection for this case series was completed under a study
protocol approved by BAMC’s Department of Clinical
Investigation Institutional Review Board.
Identification of Patients
All wound, sputum, urine, and blood culture results
completed at our hospital from March 1, 2003, to May 31,
2004, were reviewed. Those patients who had
Acinetobacter-positive cultures were then compared to all
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considered for inclusion if he had an Acinetobacter-posi-
tive culture and had been deployed to Iraq or Afghanistan
and had an admission diagnosis of injury (ICD codes
800.0–900.0). Similarly, hospital admission and laboratory
data were reviewed for the 14 months before the study
period to define the incidence of Acinetobacter infection in
hospitalized, active-duty soldiers before the onset of mili-
tary action in Iraq.
Case Definitions
Patients with either Acinetobacter contiguous focus
osteomyelitis or wound infection are included in this series.
Cases were defined as osteomyelitis if bone tissue collect-
ed during surgical procedures (primarily open debride-
ments but also including placement of external or internal
fixators or bone grafting) was positive for Acinetobacter
spp. on routine culture (5,6). In addition, patients with open
fractures or exposed bone with gross findings of infection
(purulence, necrotic tissue, or environmental contamination
with exposed bone), clinical evidence of infection (temper-
ature  >38°C, leukocyte count >12,000/µL), and
Acinetobacter spp. identified from culture of deep wound
tissue obtained intraoperatively, excluding bone, were also
defined as having osteomyelitis (7). Cases were defined as
wound infection if similar deep wound cultures were posi-
tive for Acinetobacter spp. with gross findings and clinical
evidence of infection but no exposed bone and no fracture.
Colonization with Acinetobacter was defined as a positive
culture for Acinetobacter without gross findings or clinical
evidence for infection. 
The Acinetobacter isolate was defined as MDR if it was
resistant to >3 classes of antimicrobial agents as tested by
automated antimicrobial drug–susceptibility testing (Vitek,
bioMérieux, Hazelwood, MO, USA) (8). On occasion, iso-
lates were further evaluated with disk diffusion antimicro-
bial testing for susceptibilities to alternate antimicrobial
drugs, such as colistin, or to confirm automated suscepti-
bility results. Confirmatory disk diffusion susceptibility
testing was completed only for those isolates that were
resistant to all antimicrobial agents by automated testing or
if only 1 antimicrobial drug was listed as susceptible. Disk
diffusion testing was performed in accordance with
Clinical and Laboratory Standards Institute (formerly
NCCLS) guidelines (9). Colistin susceptibility was
assumed if the zone of inhibition was >14 mm (10).
Patients were evaluated for recurrence of infection.
Many patients underwent subsequent reconstructive sur-
geries, and the bone tissue was sent for culture. Definitions
of recurrent infection followed the previously described
criteria for the case definitions with the following addi-
tions: recurrent infection was defined as having
Acinetobacter spp. isolated at the original site of infection
after completing an antimicrobial drug treatment course
for the initial infection; secondary infection was defined as
infection with a different organism at the same site as the
initial Acinetobacter infection. 
Data Collection
Both electronic and paper charts of all patients who met
case definition criteria were retrospectively reviewed for
demographic, diagnostic, and treatment data. Laboratory
results were reviewed for Acinetobacter species isolated
and antimicrobial drug susceptibilities. Patients were also
interviewed either in person or by telephone to confirm
mechanism of injury, length of antimicrobial drug treat-
ment course, recurrence of infection, subsequent hospital
admissions, and clinical outcome of the sustained injury
and infection (resolved, continuing convalescence, or
amputation). Follow-up was defined as the time from com-
pleting the initial antimicrobial treatment course to the date
of the study interview. 
Results
Case Inclusion Criteria
From March 1, 2003, to May 31, 2004, a total of 24,114
cultures (blood, urine, wound, sputum) were completed in
our hospital. Of these, 145 (0.6%) were positive for
Acinetobacter spp. During the same period, 237 active-
duty patients were admitted to our facility with the admis-
sion diagnosis of injury (Figure). Of these admitted
soldiers, 151 (64%) had been deployed to OIF/OEF.
Cultures of blood, wound, sputum, urine, or skin were
obtained for 84 of these patients; 48 (32% of admitted
deployed soldiers) were positive for Acinetobacter spp. Of
these, 30 (63%) represented clinical infection; the remain-
ing 18 represented colonization with Acinetobacter. Of
those patients with cultures that represented clinical infec-
tion, 23 met the case definition for Acinetobacter
osteomyelitis (Table 1) or Acinetobacter wound infection
(Table 2). During the 14 months before the study period,
only 2 active-duty soldiers, of 326 admitted to our facility,
had any Acinetobacter  infection. The incidence of
Acinetobacter infection during the study period represents
a significant increase when compared to the control period
(p<0.01 by 2-tailed Fisher exact test).
Demographics
All patients included in this series had been transferred
to BAMC through the military airmobile medical evacua-
tion system. All, excluding one, were evacuated through,
and admitted for at least 1 day to, Landstuhl Army Medical
Center in Landstuhl, Germany; 3 patients were admitted to
a second US Army medical center before admission to
BAMC. The median time from injury to admission at
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an time from injury to identification of infection was also
6 days (range 3–12 days). Acinetobacter infection was ini-
tially identified at BAMC in 15 of the 23 patients; the
remainder were identified at a previous medical center.
None were initially diagnosed prior to evacuation from
Iraq or Afghanistan. The median age of the patients was 26
years (range 20–48), and all but 2 were men. Patients were
generally stable on admission to BAMC and did not
require admission to an intensive care unit. 
Microbiologic Data
Patients with Acinetobacter osteomyelitis primarily had
bone tissue collected during surgical procedures that was
culture-positive for A. calcoaceticus-baumannii complex.
This was the only species and organism identified in all
initial tissue cultures. Ten patients had deep wound cul-
tures, excluding bone tissue, that were positive for A. cal-
coaceticus-baumannii complex. Five (patient numbers 4,
9, 10, 11, and 15, Table 1) had open fractures with environ-
mental contamination and signs of infection that met the
case definition of osteomyelitis. The remaining 5 (Table 2)
did not meet criteria for diagnosis of osteomyelitis and
were diagnosed with wound infection. Two of these
patients had burn injuries. Cultures of debrided soft tissue
in these 2 patients were positive for Acinetobacter within
the first 8 days of hospitalization, and pathologic evalua-
tion of tissue demonstrated invasive infection. Patient no.
22 had a soft tissue wound culture positive on hospital day
5 (postinjury day 9); patient no. 23 had a soft tissue wound
culture positive on hospital day 8 (postinjury day 10). 
Antimicrobial Drug–susceptibility Data
Thirty-eight cultures from the 23 patients reported in
this study were positive for Acinetobacter spp. (Table 4).
Twenty-nine isolates were MDR, as tested by automated
susceptibility testing. All but 4 of the MDR isolates were
susceptible to imipenem, and no imipenem resistance
developed in the 15 patients who received this drug during
therapy. Three of these 4 isolates were susceptible only to
amikacin. Of the 25 imipenem-susceptible MDR
Acinetobacter isolates, 10 demonstrated resistance to all
other tested antimicrobial agents. Other isolates were sus-
ceptible to only 1 other antimicrobial agent: 7 were also
susceptible to amikacin, 3 to ampicillin/sulbactam, 2 to
tobramycin, and 1 to trimethoprim/sulfamethoxazole. Nine
isolates were not MDR. These isolates were susceptible to
>3 classes of the tested antimicrobial agents. Three MDR
isolates were tested for susceptibility to colistin; all 3 were
susceptible by disk diffusion testing. One was susceptible
only to imipenem, 1 to amikacin alone, and 1 to both
amikacin and ceftazidime. 
Therapy
Antimicrobial drug treatment of these infections was
based on susceptibility testing, and all patients with
osteomyelitis underwent multiple surgical debridements of
necrotic bone. Ten of the patients with osteomyelitis were
treated with dual antimicrobial agents, 7 with monothera-
py, and 1 with surgical debridement alone. Only patients
with osteomyelitis received dual antimicrobial drug thera-
py. Of the 10 treated with dual therapy, 5 had MDR
Acinetobacter  spp. and 5 had non-MDR Acinetobacter
spp. isolated. The primary combination of antimicrobial
agents was imipenem (500 mg every 6 h) in combination
with high-dose amikacin (15–20 mg/kg daily). In a few
instances, when imipenem was not active against the iso-
lated organism, ampicillin/sulbactam or ceftazidime was
used if either was active against the particular isolate
(Table 1). Of the 7 treated with monotherapy, 5 had MDR
Acinetobacter isolated. All patients with wound infection
received monotherapy based on antimicrobial drug–sus-
ceptibility testing results. 
Follow-up
The follow-up period was 1–23 months (mean 9
months). During this time, no Acinetobacter infections
recurred at any site, including the bloodstream. Seven sec-
ondary infections occurred, 6 in those with an initial diag-
nosis of osteomyelitis and 1 with wound infection. Four
occurred in patients with MDR Acinetobacter  (3 with
osteomyelitis and 1 with wound infection). These secondary
infections primarily involved other resistant nosocomial
pathogens (see expanded online Tables 1 and 2, available at
http://www.cdc.gov/ncidod/eid/vol11no08/05-0103.htm). 
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Figure. Flow chart illustrating active-duty soldier admissions to
Brooke Army Medical Center from March 1, 2003, to May 31,
2004, and those who met case definitions for Acinetobacter
osteomyelitis or wound infection. *Soldiers with diagnosis of injury,
ICD codes 800.0–900.0. OIF/OEF, Operation Iraqi Freedom/
Operation Enduring Freedom.Control Period
During the 14 months before March 2003, only 2
active-duty soldiers had Acinetobacter infection. Asoft tis-
sue infection with Acinetobacter developed in 1 soldier
with a history of bullous pemphigoid. Bacteremia with
Acinetobacter developed in the other soldier, who had a
history of Ewing sarcoma. The latter Acinetobacter isolate
was not a MDR organism and was treated with imipenem
(500 mg parenterally) for 14 days. 
Discussion
The 23 cases observed during the study period repre-
sent a significant increase in the incidence of clinical
infection with Acinetobacter in our facility. Similarly, the
rate of blood, wound, or urine cultures positive for
Acinetobacter species increased 3-fold during the study
period as compared to the control time period (data not
shown). This increase and the influx of severe extremity
infection due to MDR Acinetobacter species posed con-
siderable challenges. The foremost was determining
appropriate therapy for osteomyelitis caused by MDR
Acinetobacter species without institutional or historical
experience to guide us. In addition, increasing prevalence
of this MDR gram-negative organism in our facility man-
dated new infection control procedures to limit nosoco-
mial spread. Finally, the occurrence of Acinetobacter
wound infection was somewhat unexpected, and initially
the reservoir for infection was unclear and generated
much debate. Recent investigation by the military med-
ical and research community suggests that these are noso-
comial infections; however, their exact source remains
unclear. 
Most Acinetobacter infections reported in the literature
reflect nosocomial Acinetobacter, as hospitalized patients
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extremes of age, and relative states of immunocompromise
(4). Acinetobacter species can cause infection in any organ
system, including bacteremia, pneumonia, endocarditis,
meningitis, urinary tract infection, intraabdominal abscess,
osteomyelitis, soft tissue infection, and surgical site infec-
tions (11). Data collected from a review of sentinel hospi-
tals in the United States demonstrated that 1.5% of all
nosocomial bloodstream infections were due to
Acinetobacter species (12). Crude death rates associated
with nosocomial Acinetobacter  infection are 19%–54%
(12–15). The difficulty in treating these infections is not
due to any excessive virulence of the organism per se but
rather to its antimicrobial drug resistance. Many nosoco-
mial isolates are resistant to >3 classes of antimicrobial
agents, which classifies them as MDR organisms (8,12). A
common susceptibility pattern in this case series was
resistance to all antimicrobial agents except imipenem and
amikacin. 
When these patients were first evaluated, data to guide
therapeutic decisions were limited. Previous reported
experience with osteomyelitis caused by Acinetobacter
species is scant. It has been described after a hamster bite
in an 8-year-old boy (16) and in a patient who previously
had an artillery fragment injury that caused an open frac-
ture of the right femur (17). Other reviews have described
osteomyelitis as a sequela of infection with Acinetobacter
species but did not report details of therapy or follow up
(4,11). Patients in our case series primarily received
extended dual antimicrobial–drug therapy based on
RESEARCH
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Combination therapy has been shown to decrease the risk
for development of more highly resistant organisms, which
has been reported when single agents are used alone (18).
While on this antimicrobial regimen, patients demonstrat-
ed clinical improvement with marked reduction of inflam-
matory markers. Many of these patients had internal
stabilizing hardware placed into the infected area at the
time of diagnosis of infection. This hardware remained in
place at the completion of parenteral therapy. In these sit-
uations, when the causative organism was susceptible to
oral antimicrobial agents, oral suppressive therapy was
continued as long as the stabilizing hardware remained in
place. In most cases, however, because of extended antimi-
crobial drug resistance, no oral agents maintained activity
against the Acinetobacter isolate. Once those infected with
MDR isolates demonstrated clinical improvement and nor-
malization of inflammatory markers, antimicrobial drug
therapy was discontinued without continuing long-term
suppressive therapy (see expanded online Tables 1 and 2,
available at http://www.cdc.gov/ncidod/eid/vol11no08/
05-0103.htm). 
During the follow-up period, no recurrent episodes of
Acinetobacter osteomyelitis have occurred. The relative
brevity of follow-up is a limitation of this study. The ulti-
mate outcome for these patients will not be known for
many years, as they have increased risk for recurrent infec-
tion throughout their lifetime. In addition, Acinetobacter
organisms do not possess substantial inherent virulence.
None of the patients in this series failed therapy, and none
died because of Acinetobacter infection. Such is not the
case in outbreaks among immunocompromised or inten-
sive care patients, in whom Acinetobacter infection leads
to increased mortality (12–15). The successful outcomes in
this case series may be a reflection of the youth and gener-
al good health of the soldiers infected. 
MDR  Acinetobacter is an important nosocomial
pathogen with multiple recent outbreaks reported (18–22).
It has the capacity to survive in dry environments (23,24),
which increases the risk for nosocomial transmission. The
increasing prevalence of MDR Acinetobacter in our facil-
ity led to new infection control procedures. Currently, all
injured soldiers admitted to our facility returning from
OIF/OEF are placed in contact isolation. Screening cul-
tures of the axilla, groin, and any open wound are complet-
ed to assess for colonization with MDR Acinetobacter,
which was identified in 18 of 151 admitted soldiers during
the study period (Figure). If all cultures taken on admis-
sion are negative, the soldier is then removed from contact
isolation. Soldiers with wound infection or osteomyelitis
caused by MDR Acinetobacter are kept in contact isolation
for the duration of hospitalization. Implementation of these
types of infection control procedures has limited nosoco-
mial spread in previously reported outbreaks (18,20,22),
which is the goal of our current policy, in addition to con-
trolling the continuing reservoir of this organism. 
As previously noted, we initially suspected that colo-
nized soldiers themselves were the reservoir for MDR
Acinetobacter, and that this colonization was obtained
from the environment. This hypothesis was based on 2
facts. First, these organisms are ubiquitous in the environ-
ment (4,25), and inoculation of these organisms into war
wounds during traumatic blast, shrapnel, or projectile
injuries seemed to be plausible. Second, Acinetobacter
spp. had previously been described as common pathogens
in war wounds (3), supporting the initial hypothesis.
However, these infections are apparently similar to recent-
ly reported nosocomial MDR Acinetobacter infections.
Investigation into the cause of these infections is ongoing,
but the source is unlikely to be environmental. Multiple
follow-up soil samples have not yielded Acinetobacter, yet
it has been recovered from environmental cultures within
field medical facilities. The final outcome of this investi-
gation is pending further analysis. 
Data from this case series demonstrate that highly
resistant Acinetobacter infection, including osteomyelitis,
can be successfully treated with appropriate surgical
debridement, directed antimicrobial drug therapy, and
careful follow-up. Our patients responded to this multifac-
eted approach, although their final outcome will not be
determined for several years. These patients continue to be
followed for recurrence of MDR Acinetobacter infection.
Clearly, guided therapy based on antimicrobial drug sus-
ceptibility leads to suppression of recurrent infection up to
23 months. Most of the patients in this series did not
receive extended continuation therapy with oral antimicro-
bial agents; whether such therapy would provide added
benefit is unclear. However, few antimicrobial drug
options are currently available, with none soon to be
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negative organisms. Increasing prevalence of these types
of infections highlights the necessity for newer antimicro-
bial agents with activity against these organisms.
Dr. Davis is a fellow in infectious disease at BAMC, Ft. Sam
Houston, Texas. His primary research interest is nosocomial
methicillin-resistant Staphylococcus aureus infections. 
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